Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells

详细信息    查看全文

• 作者：Ling-Yi Xiao^a ; Wai-Ming Kan^a ; ^b ; ^{Vincent@mail.ncku.edu.tw}
• 关键词：cAMP ; PKA ; DNA damaging agents ; CML
• 刊名：European Journal of Pharmacology
• 出版年：2017
• 出版时间：5 January 2017
• 年：2017
• 卷：794
• 期：Complete
• 页码：201-208
• 全文大小：1766 K
• 卷排序：794

文摘

Cyclic adenosine monophosphate (cAMP) regulates many vital functions such as metabolism, proliferation, differentiation and death. Depending on cell types and stimulators, cAMP could either promote or attenuate cell death. cAMP signal can be transduced by protein kinase A (PKA) and/or exchange protein directly activated by cAMP (EPAC). In CML cells, cAMP may suppress their proliferation and enhance their differentiation. However, the role of cAMP on DNA damaging agent toxicity and the mechanism involved has not been studied. In this study, we studied the effect of cAMP on the sensitivity of CML cells to DNA damaging agents. We observed that forskolin (FSK) and dibutyryl-cAMP (DBcAMP) decreased cisplatin and etoposide-induced cell death in K562 cells. Moreover, PKA activator prevented K562 cells from DNA damaging agent-induced cell death while EPAC activator had no effect. Furthermore, we found that the PKA subtype, PKAIA, was involved in cAMP-attenuated resistance in K562 cells. Taken together, our results suggest that increased cAMP level confers CML cells to acquire a novel mechanism against DNA damaging agent toxicity via PKAIA. Thus, PKAIA inhibitor may be helpful in overcoming the resistance to DNA damaging agents in CML cells.